Speech-Language Pathologists in Torrington, CT Accepting Medicare

5 Speech-Language Pathologists found. Showing 1 - 5

Hillary Marcinko, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 157 Litchfield St, Torrington, CT 06790 Phone: 860-605-4871

Deborah P Rabeuf, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 157 Litchfield St, Torrington, CT 06790 Phone: 860-294-7473    Fax: 860-361-9375

Michelle Nicole Steck, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 376 Goshen Road, Torrington, CT 06790 Phone: 610-925-1160

Rachel Schleker, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 157 Litchfield St, Torrington, CT 06790 Phone: 203-250-9663    Fax: 203-699-9641

Sharon Kaye Birkenbuel, MACCCSLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 733 East Main Street, Torrington, CT 06790 Phone: 860-496-7246    Fax: 860-496-0553

News Archive

Fasting reduces inflammation and improves chronic inflammatory diseases, study finds

Fasting regimens have gained public and scientific interest in recent years, but fasting shouldn't be dismissed as a fad. In a study published in Cell, Mount Sinai researchers found that fasting reduces inflammation and improves chronic inflammatory diseases without affecting the immune system's response to acute infections.

The deep divide: State borders create Medicaid haves and have-nots

Patricia Powers went a few years without health insurance and couldn't afford regular doctor visits. So she had no idea cancerous tumors were silently growing in both of her breasts.

Inova Labs completes $10 million Series A Preferred Stock financing

Inova Labs, Inc. of Austin, Texas announced today the closing of the private placement of shares of its Series A Preferred Stock. The placement went to investment funds affiliated with Three Arch Partners, based in Silicon Valley, California. Inova received gross proceeds of $10.0 million from the equity financing, which will be used for nationwide and international sales expansion of its LifeChoice® portable oxygen concentrator product line, continuation of next stage developments, and working capital.

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme were hailed as 'exciting' and a 'very promising therapy' in an editorial published in Neuro-Oncology, the leading journal of the Society of Neuro-Oncology.

Read more Medical News

› Verified 3 days ago